Patent: 10,086,046
✉ Email this page to a colleague
Summary for Patent: 10,086,046
Title: | Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells |
Abstract: | The present invention relates to an agent for the treatment and/or prophylaxis of an autoimmune disease, an agent for the formation of regulatory T cells (T.sub.Reg) in an organism and various methods in which the agents according to the invention are used. |
Inventor(s): | Paulsen; Daniela (Wuppertal, DE), Brunner; Nina (Essen, DE), Bray; Dorothy (Buckinghamshire, GB) |
Assignee: | AiCuris GmbH & Co. KG (Wuppertal, DE) |
Application Number: | 15/439,845 |
Patent Claims: | see list of patent claims |
Details for Patent 10,086,046
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2028-05-08 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2028-05-08 |
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2028-05-08 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2028-05-08 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2028-05-08 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2028-05-08 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2028-05-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |